Oxidized low-density lipoprotein impairs the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Biochemical Journal

• Publication date

  2000-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1042/BJ3520277PMID 11085919PMCID PMC1221457
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the inhibitory effects of ApoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation.

  1999cited by this paper
• Lysophosphatidylcholine Decreases the Synthesis of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells

  1998cited by this paper
• An endothelial receptor for oxidized low-density lipoprotein

  1997cited by this paper
• Alterations in the structure of apolipoprotein B-100 determine the behaviour of LDL towards thromboplastin.

  1997cited by this paper
• Expression Cloning of a Novel Scavenger Receptor from Human Endothelial Cells*

  1997cited by this paper
• Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.

  1997cited by this paper
• Tissue Factor Pathway Inhibitor Inhibits Aortic Smooth Muscle Cell Migration Induced by Tissue Factor/Factor VIIa Complex

  1997cited by this paper
• Oxidized Low Density Lipoprotein Reduces Thrombomodulin Transcription in Cultured Human Endothelial Cells through Degradation of the Lipoprotein in Lysosomes (*)

  1996cited by this paper
• Multiple proteolytic systems, including the proteasome, contribute to CFTR processing.

  1995cited by this paper
• Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation.

  1995cited by this paper
• Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

  1995cited by this paper
• Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.

  1994cited by this paper
• Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys.

  1994cited by this paper
• A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides.

  1994cited by this paper
• Expression cloning of SR-BI, a CD36-related class B scavenger receptor.

  1994cited by this paper
• Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

  1993cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• The role of lipid peroxidation and antioxidants in oxidative modification of LDL.

  1992cited by this paper
• Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.

  1992cited by this paper
• Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man.

  1992cited by this paper
• Autoantibody against oxidised LDL and progression of carotid atherosclerosis.

  1992cited by this paper
• Inhibition of the accumulation of lipid droplets in macrophage J774 by bafilomycin B1 and destruxin E.

  1992cited by this paper
• Retinoic acid stimulates expression of thrombomodulin, a cell surface anticoagulant glycoprotein, on human endothelial cells. Differences between up-regulation of thrombomodulin by retinoic acid and cyclic AMP.

  1992cited by this paper
• Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples.

  1991cited by this paper
• Receptors for modified low-density lipoproteins on human endothelial cells: different recognition for acetylated low-density lipoprotein and oxidized low-density lipoprotein.

  1991cited by this paper
• Role of oxidized low density lipoprotein in atherogenesis.

  1991cited by this paper
• Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.

  1991cited by this paper
• Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol

  1991cited by this paper
• Oxidized low‐density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation 1

  1991cited by this paper
• Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.

  1990cited by this paper
• Regulation of coagulation by a multivalent Kunitz-type inhibitor.

  1990cited by this paper
• Role of oxidatively modified LDL in atherosclerosis.

  1990cited by this paper
• Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor

  1989cited by this paper
• Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein.

  1989cited by this paper
• Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.

  1989cited by this paper
• Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

  1989cited by this paper
• Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.

  1988cited by this paper
• Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

  1988cited by this paper
• Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.

  1987cited by this paper
• Toxicity of oxidized low‐density lipoprotein to cultured fibroblasts is selective for S phase of the cell cycle

  1987cited by this paper
• Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products.

  1987cited by this paper
• Characterization of the inhibition of tissue factor in serum.

  1987cited by this paper
• INHIBITOR OF THE FACTOR VIIA-TISSUE FACTOR COMPLEX IS REDUCED IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION BUT NOT IN PATIENTS WITH SEVERE HEPATOCELLULAR DISEASE

  1987cited by this paper
• Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component.

  1985cited by this paper
• Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids.

  1984cited by this paper
• Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts.

  1976cited by this paper
• Separation of plasma lipoproteins by density-gradient ultracentrifugation.

  1975cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Impaired lipophagy in endothelial cells with prolonged exposure to oxidized low-density lipoprotein

  2020cites this paper
• Biomaterials to Prevent Post-Operative Adhesion

  2020cites this paper
• Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor.

  2018cites this paper
• Positions of Hydroxyl Groups in Chrysin are Critical for Inhibiting Plasminogen Activator Inhibitor-1 Release from Human Umbilical Vein Endothelial Cells

  2017cites this paper
• oxLDL - the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patients.

  2014cites this paper
• Propolis and its constituent chrysin inhibit plasminogen activator inhibitor 1 production induced by tumour necrosis factor-α and lipopolysaccharide

  2012cites this paper
• The Role of Complement in the Development and Manifestation of Murine Atherogenic Inflammation: Novel Avenues

  2011cites this paper
• Genomic Changes in Regenerated Porcine Coronary Arterial Endothelial Cells

  2007cites this paper
• Oxidatively Modified Low-Density Lipoproteins and Thrombosis

  2006cites this paper
• Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia.

  2006cites this paper
• Dual Role of Oxidized LDL on the NF-KappaB Signaling Pathway

  2004cites this paper
• Oxidized Phospholipids in Oxidized Low-Density Lipoprotein Reduce the Activity of Tissue Factor Pathway Inhibitor Through Association with Its Carboxy-Terminal Region

  2004cites this paper
• 外因系凝固インヒビター（TFPI）を阻害する酸化LDL中のリン脂質

  2004cites this paper
• Oxidized LDLs affect nitric oxide and radical generation in brain endothelial cells.

  2003cites this paper
• Vascular thrombogenicity induced by progressive LDL oxidation: protection by antioxidants

  2003cites this paper
• Oxidation products of phospholipid-containing delta-9 fatty acids specifically impair the activity of tissue factor pathway inhibitor.

  2002cites this paper
• Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects.

  2002cites this paper
• Oxidized Low-density Lipoprotein Associates Strongly with Carboxy-terminal Domain of Tissue Factor Pathway Inhibitor and Reduces the Catalytic Activity of the Protein

  2002cites this paper